CRP and rheumatoid arthritis: Although it may be hard to justify the use of a JAK inhibitor as a first-line advanced therapy in the majority of RA patients [48], our patient had poor prognostic factors for RA, namely high disease activity and high levels of serum CRP, anti-CCP Abs, and RF, at the first disease flare-up despite long-term MTX therapy.